GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Gross Profit

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Gross Profit : $0.00 Mil (TTM As of Dec. 2014)


View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Gross Profit?

Omni Bio Pharmaceutical's gross profit for the three months ended in Dec. 2014 was $0.00 Mil. Omni Bio Pharmaceutical's gross profit for the trailing twelve months (TTM) ended in Dec. 2014 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Omni Bio Pharmaceutical's gross profit for the three months ended in Dec. 2014 was $0.00 Mil. Omni Bio Pharmaceutical's Revenue for the three months ended in Dec. 2014 was $0.00 Mil. Therefore, Omni Bio Pharmaceutical's Gross Margin % for the quarter that ended in Dec. 2014 was N/A%.

Omni Bio Pharmaceutical had a gross margin of N/A% for the quarter that ended in Dec. 2014 => No sustainable competitive advantage


Omni Bio Pharmaceutical Gross Profit Historical Data

The historical data trend for Omni Bio Pharmaceutical's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omni Bio Pharmaceutical Gross Profit Chart

Omni Bio Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Gross Profit
Get a 7-Day Free Trial Premium Member Only - - - - -

Omni Bio Pharmaceutical Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Omni Bio Pharmaceutical's Gross Profit

For the Biotechnology subindustry, Omni Bio Pharmaceutical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omni Bio Pharmaceutical's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omni Bio Pharmaceutical's Gross Profit distribution charts can be found below:

* The bar in red indicates where Omni Bio Pharmaceutical's Gross Profit falls into.



Omni Bio Pharmaceutical Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Omni Bio Pharmaceutical's Gross Profit for the fiscal year that ended in Mar. 2014 is calculated as

Gross Profit (A: Mar. 2014 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Omni Bio Pharmaceutical's Gross Profit for the quarter that ended in Dec. 2014 is calculated as

Gross Profit (Q: Dec. 2014 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Omni Bio Pharmaceutical's Gross Margin % for the quarter that ended in Dec. 2014 is calculated as

Gross Margin % (Q: Dec. 2014 )=Gross Profit (Q: Dec. 2014 ) / Revenue (Q: Dec. 2014 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Omni Bio Pharmaceutical  (GREY:OMBP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Omni Bio Pharmaceutical had a gross margin of N/A% for the quarter that ended in Dec. 2014 => No sustainable competitive advantage


Omni Bio Pharmaceutical Gross Profit Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111
Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines